Loading
A phase 3 trial testing AZD0486 in diffuse large B-cell lymphoma, now recruiting.
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL is a phase 3 interventional study registered as NCT07215585, led by AstraZeneca, and recruiting on the registry. Official title: A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2). Planned enrolment is 420 participants (estimated). The study started in 2025-11-11 and primary completion is expected in 2030-06-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/